Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Aplastic Anemia

Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia

Bone Marrow Transplantation volume 49, pages 1481–1485 (2014)Cite this article

Subjects

Abstract

Haploidentical hematopoietic SCT (haplo-HSCT) is to be established in patients with acquired severe aplastic anemia (SAA) refractory to immunosuppressive therapy and lacking HLA-matched related or unrelated donors. Graft failure (GF) and GVHD have been major obstacles to HSCT. A total of 17 children and adolescents with SAA underwent haplo-HSCT in our center. The conditioning regimen consisted of BU, fludarabine, CY and anti-thymocyte globulin. All patients received cyclosporine, short-term MTX, mycophenolate mofetil and basiliximab for GVHD prophylaxis. Mesenchymal stem cells derived from unrelated umbilical cord were infused on day 1. Neutrophil engraftment was achieved in all 17 patients in a median time of 16 days (range 9–25 days). The median time of platelet engraftment was 22 days (range 9–95 days) in 16 patients. The cumulative incidence (CI) of II–IV acute GVHD (aGVHD) at day +100 was 30.53±11.12% and III–IV aGVHD occurred in only one patient. The CI of chronic GVHD was 21.25±13.31%. Secondary GF with autologous hematopoiesis recovery occurred in one patient. The OS was 71.60±17.00% at a median follow-up of 362 (36–1321) days. These limited promising data suggest that haplo-HSCT is feasible as a salvage therapy for children and adolescents with refractory SAA who lack matched donors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Young NS, Calado RT, Scheinberg P . Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108: 2509–2519.

    Article  CAS  Google Scholar 

  2. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073.

    Article  CAS  Google Scholar 

  3. Passweg JR, Pérez WS, Eapen M, Camitta BM, Gluckman E, Hinterberger W et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant 2006; 37: 641–649.

    Article  CAS  Google Scholar 

  4. Xu LP, Liu KY, Liu DH, Han W, Chen H, Chen YH et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant 2012; 47: 1507–1512.

    Article  CAS  Google Scholar 

  5. Wang Z, Yan H, Zhu L, Wang H . Successful unmanipulated stem cell transplantation from HLA-haploidentical 3-loci-mismatched parents in two children with severe aplastic anemia not responding to immunosuppressive therapy. Am J Hematol 2010; 85: 389–390.

    Article  Google Scholar 

  6. Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976; 48: 63–70.

    CAS  PubMed  Google Scholar 

  7. Wang HX, Wang ZD, Zheng XL, Ding L, Zhu L, Yan HM et al. Hematopoietic stem cell transplantation with umbilical cord stromal cell infusion for the treatment of aplastic anemia—a single-center experience. Cytotherapy 2013; 15: 1118–1125.

    Article  CAS  Google Scholar 

  8. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  Google Scholar 

  9. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  Google Scholar 

  10. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  Google Scholar 

  11. Gupta V, Eapen M, Brazauskas R, Carreras J, Aljurf M, Gale RP et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica 2010; 95: 2119–2125.

    Article  Google Scholar 

  12. Dong L, Wu T, Gao ZY, Zhang MJ, Kan F, Spellman SR et al. The outcomes of family haploidentical hematopoietic stem cell transplantation in hematologic malignancies are not associated with patient age. Biol Blood Marrow Transplant 2011; 17: 1205–1213.

    Article  Google Scholar 

  13. Wagner JL, Deeg HJ, Seidel K, Anasetti C, Doney K, Sanders J et al. Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives: an update of the Seattle experience. Transplantation 1996; 61: 54–61.

    Article  CAS  Google Scholar 

  14. Tzeng CH, Chen PM, Fan S, Liu JH, Chiou TJ, Hsieh RK . CY/TBI-800 as a pretransplant regimen for allogeneic bone marrow transplantation for severe aplastic anemia using HLA-haploidentical family donors. Bone Marrow Transplant 1996; 18: 273–277.

    CAS  Google Scholar 

  15. Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socié G et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica 2009; 94: 1312–1315.

    Article  CAS  Google Scholar 

  16. Kang HJ, Shin HY, Park JE, Chung NG, Cho B, Kim HK et al. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study. Biol Blood Marrow Transplant 2010; 16: 1582–1588.

    Article  CAS  Google Scholar 

  17. Dulley FL, Vigorito AC, Aranha FJ, Sturaro D, Ruiz MA, Saboya R et al. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplant 2004; 33: 9–13.

    Article  CAS  Google Scholar 

  18. Serody JS, Sparks SD, Lin Y, Capel EJ, Bigelow SH, Kirby SL et al. Comparison of granulocyte colony-stimulating factor (G-CSF)–mobilized peripheral blood progenitor cells and G-CSF–stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant 2000; 6: 434–440.

    Article  CAS  Google Scholar 

  19. Ji SQ, Chen HR, Wang HX, Yan HM, Zhu L, Liu J et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant 2002; 30: 861–866.

    Article  Google Scholar 

  20. Huang XJ, Chang YJ, Zhao XY . Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007; 17: 193–197.

    Article  CAS  Google Scholar 

  21. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004; 33: 597–604.

    Article  CAS  Google Scholar 

  22. Ji SQ, Chen HR, Yan HM, Wang HX, Liu J, Zhu PY et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant 2005; 36: 349–354.

    Article  CAS  Google Scholar 

  23. Fang J, Hu C, Hong M, Wu Q, You Y, Zhong Z et al. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 754–762.

    Article  CAS  Google Scholar 

  24. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007; 110: 2764–2767.

    Article  CAS  Google Scholar 

  25. Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010; 16: 838–847.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by Grant No. 81241016 from the NSFC in China.

Author information

Authors and Affiliations

  1. Department of Hematology, The General Hospital of Air Force PLA, Beijing, China

    Z Wang, X Zheng, H Yan, D li & H Wang

Authors
  1. Z Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Wang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Z., Zheng, X., Yan, H. et al. Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia. Bone Marrow Transplant 49, 1481–1485 (2014). https://doi.org/10.1038/bmt.2014.187

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.187

This article is cited by

Search

Advanced search

Quick links